Roche Holding AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
A Study to Investigate the Effect of Rifampicin on the PK of Multiple Doses of Balovaptin In Healthy Volunteers
- First Posted Date
- 2018-07-16
- Last Posted Date
- 2019-11-07
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 16
- Registration Number
- NCT03586726
- Locations
- 🇳🇱
Pra International Group B.V, Groningen, Netherlands
A Phase II Study Comparing The Efficacy Of Venetoclax + Fulvestrant Vs. Fulvestrant In Women With Estrogen Receptor-Positive, Her2-Negative Locally Advanced Or Metastatic Breast Cancer Who Experienced Disease Recurrence Or Progression During Or After CDK4/6 Inhibitor Therapy
- Conditions
- Estrogen Receptor-positive (ER+)/Human Epidermal Growth Factor Receptor (HER2)-Negative Locally Advanced or Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2018-07-12
- Last Posted Date
- 2022-06-28
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 103
- Registration Number
- NCT03584009
- Locations
- 🇺🇸
University of Maryland Medical Center, Baltimore, Maryland, United States
🇺🇸Nebraska Hematology Onco, PC, Lincoln, Nebraska, United States
🇦🇺Mater Hospital; Patricia Ritchie Centre for Cancer Care and Research, North Sydney, New South Wales, Australia
A Study to Investigate the Effect of Itraconazole on the PK of Multiple Doses of Balovaptan in Healthy Volunteers
- First Posted Date
- 2018-07-09
- Last Posted Date
- 2019-11-04
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 15
- Registration Number
- NCT03579719
- Locations
- 🇳🇱
Pra International Group B.V, Groningen, Netherlands
A Double-Blind Single-Ascending Dose (SAD) and Multiple-Ascending Dose (MAD) Study to Investigate the Safety, Tolerability, and Pharmacokinetics of RO7049389 in Healthy Chinese Participants
- Conditions
- Hepatitis B Virus
- Interventions
- Drug: RO7049389Drug: Placebo
- First Posted Date
- 2018-06-27
- Last Posted Date
- 2020-02-28
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 31
- Registration Number
- NCT03570658
- Locations
- 🇨🇳
Huashan Hospital Affiliated to Fudan University, Shanghai City, China
The Effectiveness Of Atezolizumab In Patients With Locally-Advanced Or Metastatic Non-Small Cell Lung Cancer After Prior Chemotherapy
- First Posted Date
- 2018-06-18
- Last Posted Date
- 2023-09-01
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 358
- Registration Number
- NCT03559647
- Locations
- 🇩🇪
Dres. Michael Maasberg Marion Schmitz und Maria Theresia Keller, Mayen, Germany
🇩🇪Joh. Wesling Klinikum Minden; Klinik fuer Hämatologie und Onkologie, Minden, Germany
🇩🇪Friedrich-Ebert-Krankenhaus Klinik f. Hämatologie/ Onkologie u. Nephrologie, Neumunster, Germany
A Study to Assess the Feasibility of an E-Health System (ZEMY) Designed to Manage Symptoms in Participants With Breast Cancer Under Anti-Cancer Treatment
- Conditions
- Breast Cancer
- Interventions
- Device: ZEMY softwareDrug: Investigator's choice of anti-cancer treatment (except immunotherapy)
- First Posted Date
- 2018-06-15
- Last Posted Date
- 2019-07-22
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 56
- Registration Number
- NCT03558490
- Locations
- 🇫🇷
Centre Francois Baclesse; Oncologie, Caen, France
🇫🇷Hopital Prive Jean Mermoz; Cancerologie, Lyon, France
🇫🇷Centre Jean Perrin; Oncologie, Clermont Ferrand, France
A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Colorectal Cancer (Morpheus-CRC)
- Conditions
- Colorectal Cancer
- Interventions
- First Posted Date
- 2018-06-13
- Last Posted Date
- 2023-11-07
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 96
- Registration Number
- NCT03555149
- Locations
- 🇫🇷
Centre Leon Berard, Lyon, France
🇰🇷Samsung Medical Center, Seoul, Korea, Republic of
🇺🇸Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Ascertain the Optimal Starting Dose of Mircera Given Subcutaneously for Maintenance Treatment of Anemia in Pediatric Patients With Chronic Kidney Disease on Dialysis or Not Yet on Dialysis.
- Conditions
- AnemiaRenal Insufficiency, Chronic
- Interventions
- Drug: Mircera
- First Posted Date
- 2018-06-11
- Last Posted Date
- 2022-03-07
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 40
- Registration Number
- NCT03552393
- Locations
- 🇺🇸
Emory University School of Med; Pediatrics, Atlanta, Georgia, United States
🇺🇸University of Alabama at Birmingham; Pediatric Nephrology, Birmingham, Alabama, United States
🇺🇸East Carolina University; Brody School of Medicine, Greenville, North Carolina, United States
A Study of RO7172508 in Patients With Locally Advanced and/or Metastatic CEA-Positive Solid Tumors
- Conditions
- Solid Tumors
- Interventions
- First Posted Date
- 2018-05-29
- Last Posted Date
- 2020-09-03
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 26
- Registration Number
- NCT03539484
- Locations
- 🇨🇦
Princess Margaret Cancer Center, Toronto, Ontario, Canada
🇪🇸Clinica Universitaria de Navarra, Pamplona, Navarra, Spain
🇪🇸Hospital Univ Vall d'Hebron; Servicio de Oncologia, Barcelona, Spain
An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
- Conditions
- Non-Hodgkins Lymphoma
- Interventions
- First Posted Date
- 2018-05-23
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 211
- Registration Number
- NCT03533283
- Locations
- 🇧🇪
UZ Gent, Gent, Belgium
🇺🇸Novant Health Cancer Institute, Charlotte, North Carolina, United States
🇩🇰Rigshospitalet; Hæmatologisk Klinik, Klinisk Afprøvnings Team KAT, København Ø, Denmark